Photon radiotherapy for the treatment of high-grade gliomas

References

• Desmeules M, Mikkelsen T, Mao Y. Increasing incidence of primary malignant brain tumors: influence of diagnostic models. J. Natl Cancer Inst.84(6), 442–445 (1992).
   PubMed Web of Science ®Google Scholar
• Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl Cancer Inst.85(9), 704–710 (1993).
   PubMed Web of Science ®Google Scholar
• Simpson JR, Horton J, Scott C et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int. J. Radiat. Oncol. Biol. Phys.26(2), 239–244 (1993).
   PubMed Web of Science ®Google Scholar
• Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant gliomas after surgery. N. Engl. J. Med.303(23), 1323–1329 (1980).
   PubMed Web of Science ®Google Scholar
• Coffey RJ, Lunsford LD, Taylor FH. Surival after stereotactic biopsy of malignant gliomas. Neurosurgery22(3), 465–473 (1988).
   PubMed Web of Science ®Google Scholar
• Walker MD, Strike TA, Sheline GE. An analysis of dose–effect relationship in the radiotherapy of malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys.5(10), 1725–1731 (1979).
   PubMed Web of Science ®Google Scholar
• Emami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys.21(1), 109–122 (1991).
   PubMed Web of Science ®Google Scholar
• Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology30(9), 907–911 (1980).
   PubMed Web of Science ®Google Scholar
• Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys.16(6), 1405–1409 (1989).
   PubMed Web of Science ®Google Scholar
• Choucair AK, Levin VA, Gutin PH et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J. Neurosurg.65(5), 654–658 (1986).
   PubMed Web of Science ®Google Scholar
• Fiveash JB, Spencer SA. Role of radiation therapy and radiosurgery in glioblastoma. Cancer J.9(3), 222–229 (2003).
   PubMedGoogle Scholar
• Liang BC, Thornton AF, Sandler HM, Greenberg HS. Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J. Neurosurg.75(4), 559–563 (1991).
   PubMed Web of Science ®Google Scholar
• Oppitz U, Maessen D, Zunterer H, Richter S, Flentje M. 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother. Oncol.53(1), 53–57 (1999).
   PubMed Web of Science ®Google Scholar
• Raaphorst GP, Feeley MM, Da Silva VF, Danjoux CE, Gerig LH. A comparison of heat and radiation sensitivity of three human gliomas cell lines. Int. J. Radiat. Oncol. Biol. Phys.17(3), 615–622 (1989).
   PubMed Web of Science ®Google Scholar
• Douglas JG, Stelzer KJ, Mankoff DA et al. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int. J. Radiat. Oncol. Biol. Phys.64(3), 886–891 (2006).
   PubMedGoogle Scholar
• Solberg TD, Agazaryan N, Goss BW, Dahlbom M, Lee SP. A feasibility study of 18F-fluorodeoxyglucose positron emission tomography targeting and simultaneous integrated boost for intensity-modulated radiosurgery and radiotherapy. J. Neurosurg.101, 381–389 (2004).
   PubMedGoogle Scholar
• Chang J, Thakur S, Perera G et al. Image-fusion of MR spectroscopic images for treatment planning of gliomas. Med. Phys.33(1), 32–40 (2006).
   PubMedGoogle Scholar
• Narayana A, Yamada J, Berry S et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int. J. Radiat. Oncol. Biol. Phys.64(3), 892–897 (2006).
   PubMed Web of Science ®Google Scholar
• Hermanto U, Frija EK, Lii, MJ, Chang EL, Mahajan A, Woo SY. Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high grade gliomas: does IMRT increase the integral dose to normal brain? Int. J. Radiat. Oncol. Biol. Phys.67(4), 1135–1144 (2007).
   PubMed Web of Science ®Google Scholar
• Tanaka M, Ino Y, Nakagawa K, Tago M, Todo T. High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. Lancet Oncol.6(12), 953–960 (2005).
   PubMedGoogle Scholar
• Chan JL, Lee SW, Fraass BA et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J. Clin. Oncol.20(6), 1635–1642 (2002).
   PubMed Web of Science ®Google Scholar
• Floyd NS, Woo SY, Teh BS et al. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys.58(3), 721–726 (2004).
   PubMed Web of Science ®Google Scholar
• Sultanem K, Patrocinio H, Lambert C et al. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial. Int. J. Radiat. Oncol. Biol. Phys.58(1), 247–252 (2004).
   PubMed Web of Science ®Google Scholar
• Prados MD, Wara WM, Sneed PK et al. Phase III trial of accelerated hyperfractionatino with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys.49(1), 71–77 (2001).
   PubMed Web of Science ®Google Scholar
• Miralbell R, Mornex F, Greiner R et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. J. Clin. Oncol.17(10), 3143–3149 (1999).
   PubMed Web of Science ®Google Scholar
• Coughlin C, Scott C, Langer C, Coia L, Curran W, Rubin P. Phase II, two-arm RTOG trials (94–11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (>20 or < or = 20 cm2, respectively) in the treatment of newly-diagnosed radiosurgery-ineligible gliomblastoma multiforme patients. Int. J. Radiat. Oncol. Biol. Phys.48(5), 1351–1358 (2000).
   PubMedGoogle Scholar
• Lutterbach J, Weigel P, Guttenberger R, Hinkelbein W. Accelerated hyperfractionated radiotherapy in 149 patients with glioblastoma multiforme. Radiother. Oncol.53(1), 49–52 (1999).
   PubMed Web of Science ®Google Scholar
• Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumor Working Party. Br. J. Cancer64(4), 769–774 (1991).
   PubMed Web of Science ®Google Scholar
• Loeffler JS, Alexander E, Shea WM et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J. Clin. Oncol.10(9), 1379–1385 (1992).
   PubMed Web of Science ®Google Scholar
• Mehta MP, Masciopinto J, Rozental J et al. Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int. J. Radiat. Oncol. Biol. Phys.30(3), 541–549 (1994).
   PubMed Web of Science ®Google Scholar
• Buatti JM, Friedman WA, Bova FJ, Mendenhall WM. Linac radiosurgery for high-grade gliomas: the University of Florida experience. Int. J. Radiat. Oncol. Biol. Phys.32(1), 205–210 (1995).
   PubMedGoogle Scholar
• Gannett D, Baldassarre S, Lulu B, Adair T, Verdi C, Hamilton A. Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas. Int. J. Radiat. Oncol. Biol. Phys.33(2), 461–468 (1995).
   PubMedGoogle Scholar
• Sarkaria JN, Mehta MP, Loeffler JS et al. Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Int. J. Radiat. Oncol. Biol. Phys.32(4), 931–941 (1995).
   PubMed Web of Science ®Google Scholar
• Larson DA, Gutin PH, McDermott M et al. γ-knife for glioma: selection factors and survival. Int. J. Radiat. Oncol. Biol. Phys.36(5), 1045–1053 (1996).
   PubMedGoogle Scholar
• Kondziolka D, Flickinger JC, Bissonette DJ, Bozik M, Lunsford LD. Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery41(4), 776–783 (1997).
   PubMed Web of Science ®Google Scholar
• Shenouda G, Souhami L, Podgorsak EB et al. Radiosurgery and accelerated radiotherapy for patients with glioblastoma. Can. J. Neurol. Sci.24(2), 110–115 (1997).
   PubMedGoogle Scholar
• Cardinale RM, Schmidt-Ullrich RK, Benedict SH, Zwicker RD, Han DC, Broaddus WC. Accelerated radiotherapy regimen for malignant gliomas using stereotactic concomitant boosts for dose escalation. Radiat. Oncol. Invest.6, 175–181 (1998).
   PubMedGoogle Scholar
• Shrieve DC, Alexander E, Black PM et al. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J. Neurosurg.90, 72–77 (1999).
   PubMed Web of Science ®Google Scholar
• Regine WF, Patchell RA, Strottmann JM, Meigooni A, Sanders M, Young B. Combined stereotactic split-course fractionated γ knife radiosurgery and conventional radiation therapy for unfavorable gliomas: a Phase I study. J. Neurosurg.93(Suppl. 3), 37–41 (2000).
   PubMedGoogle Scholar
• Nwokedi EC, DiBiase SJ, Jabbour S, Herman J, Amin P, Chin LS. γ knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery50(1), 41–47 (2002).
   PubMed Web of Science ®Google Scholar
• Prisco FE, Weltman E, de Hanriot RM, Brandt RA. Radiosurgical boost for primary high-grade gliomas. J. Neurooncol.57(2), 151–160 (2002).
   PubMed Web of Science ®Google Scholar
• Baumert BG, Lutterbach J, Bernays R, Davis JB, Heppner FL. Fractionated stereotactic radiotherapy boost after post-operative radiotherapy in patients with high-grade gliomas. Radiother. Oncol.67, 183–190 (2003).
   PubMedGoogle Scholar
• Ulm AJ, Friedman WA, Bradshaw P, Foote KD, Bova FJ. Radiosurgery in the treatment of malignant gliomas: the University of Florida experience. Neurosurgery47, 512–517 (2005).
   Google Scholar
• Yoshikawa K, Saito K, Kajiwara K, Nomura S, Ishihara H, Suzuki M. CyberKnife stereotactic radiotherapy for patients with malignant glioma. Minim. Invasive Neurosurg.49(2), 110–115 (2006).
   PubMedGoogle Scholar
• Curran WJ, Scott CB, Weinstein AS et al. Survival comparison of radiosurgery-eligible and – ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83–02. J. Clin. Oncol.11, 857–862 (1993).
   PubMed Web of Science ®Google Scholar
• Irish WD, Macdonald DR, Cairncross JG. Measuring bias in uncontrolled brain tumor trials – to randomize or not to randomize? Can. J. Neurol. Sci.24(4), 307–312 (1997).
   PubMedGoogle Scholar
• Souhami L, Seiferheld W, Brachman D et al. Randomized comparison of stereotactic radiosurgery followeed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93–05 protocol. Int. J. Radiat. Oncol. Biol. Phys.60(3), 853–860 (2004).
   PubMed Web of Science ®Google Scholar
• Shaw E, Scott C, Souhami L et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90–05. Int. J. Radiat. Oncol. Biol. Phys.47(2), 291–298 (2000).
   PubMed Web of Science ®Google Scholar
• Cardinale R, Won M, Choucair A et al. A Phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int. J. Radiat. Oncol. Biol. Phys.65(5), 1422–1428 (2006).
   PubMedGoogle Scholar
• Laing RW, Warrington AP, Graham J, Britton J, Hines F, Brada M. Efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent gliomas (Phase I/II study). Radiother. Oncol.27(1), 22–29 (1993).
   PubMed Web of Science ®Google Scholar
• Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int. J. Radiat. Oncol. Biol. Phys.45(5), 1133–1141 (1999).
   PubMed Web of Science ®Google Scholar
• Hsieh PC, Chandler JP, Bhangoo S et al. Adjuvant γ-knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme. Neurosurgery57, 684–692 (2005).
   PubMedGoogle Scholar
• Mahajan A, McCutcheon IE, Suki D et al. Case-control study of stereotactic radiosurgery for recurrent glioblastoma multiforme. J. Neurosurg.103, 210–217 (2005).
   PubMed Web of Science ®Google Scholar
• Vordermark D, Kolbl O, Ruprecht K, Vince GH, Breatengeier K, Flentje M. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer5, 55–61 (2005).
   PubMedGoogle Scholar
• Wurm RE, Kuczer DA, Schlenger L et al. Hypofractionated stereotactic radiotherapy combined with topotecan in recurrent malignant glioma. Int. J. Radiat. Oncol. Biol. Phys.66(4), S26–S32 (2006).
   Google Scholar
• Ernst-Stecken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G. Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. J. Neurooncol.81, 287–294 (2007).
   PubMedGoogle Scholar
• Kohshi K, Yamamoto H, Nakahara A, Katoh T, Takagi M. Fractionated stereotactic radiotherapy using γ unit after hyperbaric oxygenation on recurrent high-grade gliomas. J. Neurooncol.82, 297–303 (2007).
   PubMed Web of Science ®Google Scholar
• Lederman G, Wronski M, Arbit E et al. Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am. J. Clin. Oncol.23(2), 155–159 (2000).
   PubMed Web of Science ®Google Scholar
• Grosu AL, Weber WA, Franz M et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys.63(2), 511–519 (2005).
   PubMed Web of Science ®Google Scholar
• Selker RG, Shapiro WR, Burger P et al. The Brain Tumor Cooperative Group NIH Trial 87–01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery51(2), 343–355 (2002).
   PubMed Web of Science ®Google Scholar
• Laperriere NJ, Leung PM, McKenzie S et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int. J. Radiat. Oncol. Biol. Phys.41(5), 1005–1011 (1998).
   PubMed Web of Science ®Google Scholar